New Approaches for the Treatment of Civilization Diseases
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 12398
Special Issue Editor
Special Issue Information
Dear Colleagues,
Civilization diseases are called the epidemy of the 21st century. They spread globally, are non-contagious, yet lead to disability and result in over 80% of premature deaths. Living in a hurry, full of stressful stimuli, poor nutrition, as well as climate change and using stimulants are the causes that often lead to a shortening of life expectancy or significantly reduce its quality. The most often diseases of civilization include disorders of the cardiovascular system, obesity, atherosclerosis, diabetes, cancer, allergies and osteoporosis as well as disorders of the central systemsuch as mental (eg. schizophrenia) and neurodegenerative diseases (Parkinson’s and Alzheimer’s disease). The number of patients with depression, neurosis and schizophrenia is increasing. Despite the continuous progress of medical science and the introduction of new drugs to the market, the effectiveness of treatment of many diseases remains unsatisfactory. One of the major problems with pharmacotherapy is the large variability in patients' response to the drug. Therefore, it is necessary to individualize the treatment and to optimize the substances of the pharmacotherapy used. In this special issue, we invite potential authors to submit manuscripts regarding the discovery of anti-cancer, anti-diabetes, anti-tuberculosis and drugs for mental and neurodegenerative diseases. Publications covering, inter alia, the synthesis, mechanism of action and biological activity of the compounds are welcome. Both original and review article contributions will be welcome.
Dr. Monika Pitucha
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.